Luca Rastelli

Luca Rastelli is the Chief Scientific officer of Jubilant Therapeutics Inc., a subsidiary of Jubilant Pharmova Limited. Luca brings to Jubilant Therapeutics more than 20 years of oncology drug discovery and development experience, as well as business development experience ranging from startups to large pharmaceutical companies. Most recently, he was CSO at Kleo Pharmaceuticals where he led all aspects of R&D for the company and was instrumental in bringing a CD38 targeting compound based on Kleo novel ARM technology to the clinics for multiple myeloma.

Previously Luca was Vice President, Oncology at BioXcel Therapeutics where he helped bring the company to a successful IPO. He has held multiple preclinical and clinical project leadership positions at Boston Scientifics, CuraGen, Sopherion and EMD Serono (Merck Serono). He led the initial development of c-MET inhibitor TEPMETKO, approved for the treatment of METex14 positive NSCLC patients. Luca was also part of the initial development of the immuno-oncology antibody BAVENCIO, a PDL-1 inhibitor approved for several type of cancers. He received the American Brain Tumor Association's 25th Anniversary Translational grant for his work on Medulloblastoma tumors at the Department of Neuro-Oncology, MD Anderson Cancer Center. He is a named inventor on more than 10 issued patents and holds a Ph.D. in Molecular Biology from the University of Geneva.